The American health authorities announced on Friday to urgently authorize a new treatment against Covid-19, the bebtelovimab monoclonal antibodies, which remain effective against the Omicron variant.
This treatment remains active including against the sub-variant of Omicron BA.2, specified the American Medicines Agency (FDA).
Produced by the pharmaceutical group Eli Lilly, it can be administered to people at high risk of developing a severe case of the disease, from the age of 12.
In clinical trials, side effects could include itching, nausea, or vomiting.
–
